|24th January 2020||James E Dentzer||3,094||Open or private sale||$1.64||$5,076.33|
|23rd January 2020||James E Dentzer||3,658||Open or private sale||$1.69||$6,181.65|
|22nd February 2019||Marc Rubin||859||Exercise of derivative||$2.39||$2,053.01|
|22nd February 2019||Marc Rubin||859||Open or private sale||$6.02||$5,174.96|
|21st February 2019||Marc Rubin||43,326||Open or private sale||$6.02||$261,026.15|
|21st February 2019||Marc Rubin||7,000||Open or private sale||$6.00||$42,000.00|
|21st February 2019||Marc Rubin||43,326||Exercise of derivative||$2.39||$103,549.14|
|24th January 2019||James E Dentzer||3,094||Open or private sale||$1.16||$3,576.97|
|23rd January 2019||Lori Anne Kunkel||14,800||Open or private sale||$1.05||$15,581.44|
|23rd January 2019||James E Dentzer||2,397||Open or private sale||$1.09||$2,612.73|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948,CA-170, and CA-327. The company was founded in 2000 and is headquartered in Lexington, MA.